Syntopia
Description
Syntopia is an emerging start-up founded in 2025, spin-out from Laboratory of Biophysic and Evolution at ESPCI-PSL in Paris, France (PI : Dr Philippe Nghe).
Syntopia’s mission is to revolutionize preclinical testing by providing advanced microfluidic solutions for high-throughput phenotypic screening. By combining microfluidic, bioengineering and complementary AI based tools, we enable pharmaceutical companies, biotech and CROs to conduct complex drug candidate tests on highly relevant biological systems while using limited quantities of biological and chemical material, reducing operational costs and enhancing test reliability. Our solutions are fully interfaceable with common lab equipments allowing to achieve scalability even with improved complexity.
Syntopia’s ultimate goal is to better assess the efficacy and toxicity of new therapeutic options for complex diseases such as immune-oncology, neurological disorders, and rare diseases.
